Mr. Oberman brings more than 18 years of C-suite international pharmaceutical industry experience to Jay Pharma. From 2016 to 2018, Mr. Oberman was CEO of Concordia International Corp. (renamed Advanz Pharmaceutical in December 2018), an international specialty pharmaceutical company which provided a number of pharmaceutical medicines for the treatment of cancer. From 2015 to 2016, Mr. Oberman was Chief Executive Officer of Sagent Pharmaceuticals Inc, a leading hospital and long-term clinic-focused specialty pharmaceutical company. Sagent Pharmaceuticals was sold to Nichi-Iko Pharmaceutical Co. Ltd., Japan’s largest generic drug manufacturer.
From 2012 to 2014, Mr. Oberman served as President and CEO of Teva Americas Generics, where he was responsible for a region that included the U.S., Canada, and Latin America. He joined Teva in 2000 and served as President of Teva EMIA (Eastern Europe, Middle East, Israel, and Africa), where he led a diverse group of countries in achieving consistent growth. Mr. Oberman also served as the Chief Operating Officer of Teva International, and President and CEO of Teva Canada, formerly known as Novopharm Limited.
Mr. Oberman serves on the Board of Directors of Dr. Reddy’s Laboratories (NYSE: RDY). He was Vice Chairman of the Association for Accessible Medicines, Chairman of the Canadian Generic Pharmaceutical Association, served on the Associate Board of the Canadian Association of Chain Drug Stores, and was a member of the Board of Directors of the Baycrest Centre Foundation, the Electronic Commerce Council, and the Food and Consumer Products Association of Canada. Mr. Oberman holds an MBA from the Schulich School of Business, York University, and a BA from the University of Western Ontario.